MED12 and prostate carcinoma: Previous studies indicated that MED12 was found to be recurrently mutated in hormone‐associated cancers, such as prostate cancer, adrenocortical carcinoma, and uterine leiomyomas (ULs).36, 37 Among these tumors, only FAs and ULs have the nearly identical MED12 mutation spectrum in both exon location and variant codon preference, suggesting a common underlying molecule mechanism in ULs and FAs that MED12 exon 2 mutations could be associated with hormonal expression.